Ask AI
FLT3 in AML

CME

Deciphering FLT3 in AML: Biological Underpinnings, Expression Patterns, and Molecular Profiling

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: July 10, 2025

Expiration: January 09, 2026

Activity

Progress
1 2
Course Completed

References

  1. Almatani MF, Ali A, Onyemaechi S, et al. Strategies targeting FLT3 beyond the kinase inhibitors. Pharmacol Ther. 2021;225:107844.
  2. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372-4380.
  3. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110:1262-1270.
  4. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30:735-741.
  5. Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571-1583.
  6. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464.
  7. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345-1377.
  8. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia — acute myeloid leukemia (AML). seer.cancer.gov/statfacts/html/amyl.html. Accessed June 30, 2025.
  9. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209-2221.
  10. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264-278.
  11. Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011;4:36.
  12. Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686-698.
  13. Lagunas-Rangel FA, Chávez-Valencia V, Gómez-Guijosa MÁ, et al. Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res. 2017;11:328-339.
  14. Litzow MR. More flitting about FLT3. Blood. 2005;106:3331-3332.
  15. Zhi Y, Wang Z, Yao C, et al. Design and synthesis of 4-(heterocyclic substituted amino)-1H-pyrazole-3-carboxamide derivatives and their potent activity against acute myeloid leukemia (AML). Int J Mol Sci. 2019;20:5739.
  16. Novatcheva ED, Anouty Y, Saunders I, et al. FMS-Like tyrosine kinase 3 inhibitors for the treatment of acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2022;22:e161-e184.
  17. Song Y, Magenau J, Li Y, et al. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016;51:511-520.
  18. Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124:3441-3449.
  19. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.
  20. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079-1089.
  21. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776-2784.
  22. de Haas V, Ismaila N, Advani A, et al. Initial diagnostic work-up of acute leukemia: ASCO clinical practice guideline endorsement of the College of American Pathologists and American Society of Hematology Guideline. J Clin Oncol. 2019;37:239-253.
  23. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute myeloid leukemia. v.2.2025. nccn.org. Accessed June 30, 2025.
  24. Polz MF, Cavanaugh CM. Bias in template-to-product ratios in multitemplate PCR. Appl Environ Microbiol. 1998;64:3724-3730.
  25. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5:96-102.
  26. Boluda B, Rodriguez-Veiga R, Sargas C, et al. Conventional PCR versus next generation sequencing for diagnosis of FLT3, IDH and NPM1 mutations in acute myeloid leukemia: results of the PETHEMA PCR-LMA study. Cancers (Basel). 2025;17:854.
  27. Kamps R, Brandão RD, van den Bosch BJ, et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18:308.
  28. Kleppe M, Levine RL. Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med. 2014;20:342-344.
  29. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127:29-41.